Cite

HARVARD Citation

    Rutherford, S. et al. (2021). Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet. 8 (11), pp. e818-e827. [Online]. 
  
Back to record